|

Azacytidine plus CAOLD regimen Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Navy General Hospital, Beijing1

Indications

  • Refractory Peripheral T-Cell Lymphomas1
  • Relapsed Peripheral T-Cell Lymphomas1
  • Cancer1

Other1 trial

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.